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Abstract INTRODUCTION: Normal function of the hypotalamo-adrenal axis is important 
for the regulation of feto-maternal  intrauterine homeostasis including immuno-
modulating activity and may influence the timing of parturition. ACTH is pro-
duced during pregnancy by mother pituitary gland and by trophoblast cells, 
which are the place of oxytocinase production. Oxytocinase is basically secreted 
by syncytiotrophoblast cells and rises progressively during pregnancy until the 
labor. Oxytocinase may play a role as one of the main factors suppressing uterine 
contractions, controlling the vascular resistance and the volume of the retropla-
cental blood pool. 
MATERIAL AND METHODS: The study group consisted of 102 patients with preg-
nancy following infertility treatment. The assessment was provided longitudinally 
in six selected groups progressively according to the gestational age. Immunoassay 
was used to measure ACTH plasma concentration. Oxytocinase plasma activity 
was established using l-cystine-di-β-naphthylamide as a substrate.
RESULTS: Significantly increased oxytocinase plasma level was identified dur-
ing pregnancy, progressive rise was observed beginning with the first trimester 
of pregnancy, until the labor. ACTH plasma concentration was observed  to be 
at comparable level in the first and second trimester of pregnancy, while sudden 
statistically significant increase of ACTH plasma level was noted beginning with 
28th week of gestation.  
CONCLUSIONS: The assessment of ACTH and oxytocinase plasma concentration 
might be useful for the evaluation of pregnancy development. 
 
Introduction
Epilepsy is a common disease. In the USA abThe efficacy of hormonal therapy treatment depends 
on the metabolism of hormones and their effectors status, and is represented intermediately by their 
blood serum level. Each hormone is decomposed by enzymes controlled by metabolic pathways. In 
sum, enzymes are responsible for hormones effectiveness. The alteration of enzyme level influences the 
concentration of hormone, the effect depends on the hormone-enzyme and their metabolic environ-
ment balance. This phenomenon is demonstrated by, for example, the oxytocinase-oxytocin system. 
The level of biologically active oxytocin is regulated by oxytocinase activity (serum aminopeptidase 
activity) [18]. Oxytocinase may be also involved in gonadotropin releasing hormone (GnRH) degra-
dation. Hypothalamus is responsible for the regulation of neuro-endocrine system through hypota-
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lamo-adrenal axis (HPA) and hypothalamo-gonadal 
axis. The former secretes ACTH in response to stress 
stimuli, and the latter, regulates the fertility. In both of 
them steroid hormones are finally produced. ACTH is 
produced during pregnancy by mother pituitary gland 
and by trophoblast cells. 
Normal function of the HPA axis is important for the 
regulation of feto-maternal  intrauterine homestasis. It 
may influence the timing of parturition. The source of 
CRH growth during pregnancy are both pituitary cells 
and placental cells. Although it was previously sug-
gested that the pregnancy ACTH growth results from 
CRH secretion, no correlation between CRH levels 
and answer of maternal as well as fetal HPA axis was 
identified [9,30,32]. The ACTH and CRH presence 
in placental microenvironment is directly involved in 
progesterone regulation in trophoblast cells [12]. Since 
the blockade of progesterone is one of the mechanism 
possibly involved in initiation of labor, the labor results 
from the immune tolerance change. The ACTH and 
CRH might influence the immune regulation during 
pregnancy. Progesterone, necessary for normal preg-
nancy development accumulates during pregnancy and 
generally stimulates the conversion of Th0 to Th2 cells 
[33]. ACTH in not only the neuroendorcine hormone, 
but is also produced by immune cells (lymphocytes and 
macrophages), so ACTH receptor is detected  on vari-
ous immune cells [8,13]. ACTH appears to be a basic 
factor responsible for the bi-directional communication 
between neuroendocrine and immune system.
Oxytocinase (cystine amino peptidase – CAP), 
which was originally recognized during pregnancy in 
blood serum as an enzymatic activity capable of cleav-
ing synthetic substrates such as L-cystine-di-β-naph-
thylamide, is a member of mammalian zinc containing 
the family of aminopeptidases [17,18,27]. In maternal 
serum a soluble form of CAP can be detected due to the 
deletion of cytoplasmic and hydrophobic transmem-
brane domains of native form. Oxytocinase is basically 
secreted by syncytiotrophoblast cells and rises progres-
sively during pregnancy until the labor [14,29]. The 
membrane form of oxytocinase was identified also in 
skeletal muscles, heart, decidua, Graffian follicle, brain 
and human umbilical vein endothelial cells [38]. CAP 
is responsible for degradation of the following peptide 
hormones: vasopresin (AVP), oxytocin (OT), angioten-
sin III (ANG III) and it may regulate the level of these 
peptide hormones in fetal and maternal serum. This 
enzyme may play a role as one of the main factors sup-
pressing uterine contraction, controlling the vascular 
resistance and the volume of the retroplacental blood 
pool. 
The aim of our study was to evaluate the concen-
tration of blood ACTH and oxitocinase serum activ-
ity in order to establish the role of these factors in the 
materno-fetal homeostasis during pregnancy. 
Materials and Methods
Group of patients
In all cases patients consent was obtained. The 
approval for the research program from the Ethical 
Committee of the Jagiellonian University in Krakow: 
KBET/379/13/2003 was also granted. The 102 patients 
in this study were randomly selected from 250 women 
treated because of infertility at the Gynecology and 
Infertility Department of the Jagiellonian University 
between March 2003 and December 2004. The mean 
age of all patients was 30.3 (± 4.6) years, the average 
gestational age during the labor was 38.4 (± 2.0) weeks, 
average newborns birth weight 2890.3 (± 468 g), aver-
age newborns length 52.5cm (± 3.7), Apgar 9.6 (± 0.8), 
K- index of newborns maturity 11.5 (± 1.0) and parity 
1.9 (± 1.2). The patients were observed for the whole 
course of pregnancy. The assessment was provided lon-
gitudinally six times during the gestation in following 
groups: group I – pregnant women between 7th and 9th 
week of gestation, group II – between 15th and 17th 
week of pregnancy, group III – between 18th and 20th , 
group IV – between 28th and 30th , group V – between 
32nd and 33rd and group VI – between 36th and 37th 
weeks of gestation. 
Hormone assays
ACTH concentration and oxytocinase serum level 
were established totally in 612 plasma samples. It was 
assessed in whole blood samples, collected approx-
imetly 9 in the morning in silicon-coated glass tubes 
containing EDTA as an anticoagulant, and were centri-
fuged immediately in a refrigerated centrifuge. All sam-
ples were frozen at –20°C until the ACTH analysis was 
performed. Immunoassay was used to measure ACTH 
(Immulite 2000 ACTH, DPC Ltd- United States).
The CAP plasma activity was evaluated using Tuppy 
and Nesvadba method, modified by Klimek [17]. The 
assessment of oxytocinase in two pH levels using the 
same substrate (l-cystine-di-β-naphthylamide) results 
in obtaining two peeks of aminopeptidase’s activity 
(CAP1 – pH 7.9; and CAP2 – pH 6.7). The detailed 
method of CAP estimation was described in previous 
studies [16,22,24].
Statistical analysis
Statistical calculations were performed using Statis-
tica computer program (StatSoft, Poland). The normal 
distribution of value of ACTH and CAP was checked 
by means of the Shapiro-Wilk test. Mann-Whitney U 
test was applied to compare the differences between 
parametric data. A value of p < 0.05 was considered as 
significant.
Results
The analysis of CAP1 and CAP 2 serum level and 
ACTH concentration was performed in a group of 102 
pregnant women. The assessment was provided longi-
tudinally in all selected groups (from group I to group 
VI) (Table 1.)
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High statistically significant correlation was found 
between the CAP1 and CAP2 serum levels (r=0.95, 
p=0.0001). No correlation was observed between 
ACTH serum concentration and the levels of CAP1 
and CAP2, respectively r=0.18 and r=0.11). Enzymes 
levels rose progressively with the gestational age and 
the differences between each groups were statistically 
significant (p<0.0001). 
The level of ACTH was at comparable levels in I, 
II, III groups (gestational age between 7th and 20th 
weeks of pregnancy). Beginning with 28th week of 
gestation ACTH concentration started to rise, the dif-
ference between 7th–20th (groups I, II, III) and 28th 
week of gestation (group IV) was statistically significant 
(p=0.001). Progressive increase of ACTH maintained 
until the labor, and the difference between group IV 
and VI was statistically significant (p=0.001), while the 
growth of ACTH serum level between 30rd and 33th 
weeks of gestation was not statistically significant, how-
ever the tendency of ACTH rise was observed. 
The comparative analysis between ACTH and oxy-
tocinase (CAP1 and CAP2) serum levels before and 
after 28th week of gestation was also performed. Figure 
1 and 2 demonstrate the results of ACTH and CAP1 
and CAP2 levels comparison. 
Discussion
In the present study, significantly increased oxy-
tocinase level was identified during pregnancy, with 
a progressive growth from early pregnancy until the 
labor. ACTH plasma concentration was observed to 
be at comparable level in the first and second trimes-
ters of pregnancy, while sudden statistically significant 
increase of ACTH plasma level was noted beginning 
28th week of gestation.  
Maternal pituitary ACTH secretion and plasma 
ACTH levels rise during pregnancy. Additional secre-
tion of ACTH from placenta takes place during preg-
nancy. Maximum plasma concentration of ACTH was 
Table 1: ACTH and oxytocinase (CAP1 and CAP2) concentration according to progressive rise of gestational age of pregnant women.
Groups ACTH (pg/ml) CAP1 (µmol/l/min) CAP2 (µmol/l/min)
(gestational age) serum level +SD serum level +SD serum level +SD
 (range) (range) (range)
Group I – 7÷9 weeks 12.1 ± 5.8 0.59 ± 0.2* 1.35 ± 0.3#
(n=102) (5 ÷ 2.4) (0.3 ÷ 1.7) (0.1 ÷ 2.3)
Group II – 15÷17 weeks 11.3 ± 4.8 1.21 ± 0.5* 1.8 ± 0.4#
(n=102) (5 ÷ 23.7) (0.4 ÷ 3.4) (1.1 ÷ 3.4)
Group III – 18÷20 weeks 11.8 ± 5.0 1.61 ± 0.7* 2.11 ± 0.5#
(n=102) (4.9 ÷ 29.3) (0.4 ÷ 5.0) (1.1 ÷ 4.5)
Group IV – 28÷30 weeks 15.1 ± 5.3 3.41 ± 1.4* 3.45 ± 1.6#
(n=102) (5.4 ÷ 29.3) (1.3 ÷ 7.9) (2.0 ÷ 6.5)
Group V – 32÷33 weeks 19.3 ± 8.9 4.9 ± 2.5* 4.5 ± 1.9#
(n=102) (5.4 ÷ 51) (1.3 ÷ 14) (2 ÷12.6)
Group VI – 36÷37 weeks 22.9 ± 1.0 7.5 ± 2.3* 6.2 ± 1.8#
(n=102) (5.4 ÷ 52.3) (3.2 ÷ 14.9) (3.4 ÷12.6)
 
# The differences statistically significant p<0.01; n-number of patients
* The differences statistically significant p<0.01; n-number of patients
Figure 1. Presents the ACTH plasma concentration changes 
according to growth of gestational age (**p<0.01)
Figure 2. Demonstrates the changes of oxytocinase serum 
activity during pregnancy (*p<0.001).
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reported in 34th  week of gestation with a significant 
fall in late pregnancy [26]. Our study does not confirm 
this observation, since the ACTH plasma concentration 
starts to increase beginning 28th week of gestation and 
progressively rise until the labor. Similarly to our study, 
progressively the growing ACTH level with the develop-
ment of gestation was shown by Jeschke et al [12]. The 
highest ACTH level identified in pregnancy was noted 
during the labor [30,31]. ACTH plasma concentration 
was not associated with the progression of the labor, 
although concomitant increase of Cortisol serum level 
was observed [2]. No differences were noticed among 
ACTH plasma concentrations between patients receiv-
ing or not receiving mifepristone therapy during labor 
at term [2]. ACTH seems to modulate the endocrine 
function of throphoblast cells downregulating proges-
teron production in vitro [12]. 
The pituitary gland responds to stressful stimuli by 
rapidly increasing the secretion of adrenocorticotropin, 
which in turn increases the secretion of cortisol. Since 
placental clock was suggested to determine the length 
of gestation, maternal plasma level might be used as an 
indicator of these events increasing until the labor (cor-
tisol, ACTH, CRH) [4]. To confirm the link between 
increasing labor stress and the growing ACTH serum 
level standardized CPT (cold pressor test) was per-
formed in two groups of pregnant women, fearful and 
fearless ones. Women with fear of labor were character-
ized by reduced pain tolerance both before and after 
labor. ACTH, cortisol and beta endorphin did not differ 
between both groups, however ACTH baseline levels 
during pregnancy were significantly higher than those 
after pregnancy in both groups (with or without fear of 
labor) [34]. Contrary to this observation Ochedalski et 
al. reported that maternal pituitary response to stress 
factors grew during delivery and the ACTH plasma 
concentration raised. The rise of the ACTH serum level 
was higher in women with induced labor in comparison 
to labor with spontaneous beginning. The ACTH level 
observed during pregnancy seems to be independent 
from CRH increasing concentration because ACTH 
levels are during pregnancy within the range of no 
pregnant subject, despite extremely elevated maternal 
CRH. [30,31]. 
The highest concentration of ACTH observed in 
induced labor receiving oxytocin treatment might result 
from the modulation of anterior pituitary secretion by 
oxytocin as a central maternal regulation of the mater-
nal hypothalamo pituitary axis [30]. The differences 
of ACTH maternal plasma level observed in our study 
between 28th and 32nd week of gestation might indi-
cate that labor associated stress but also other factors 
seem to be responsible for the ACTH increase. The rise 
in the ACTH level observed immediately before normal 
time of the onset of labor might result from immuno-
logical activity changes necessary to initiation of spon-
taneous labor at term. The neuroendocrine hormone 
ACTH alters immune responses and may be a factor 
in mediating stress-induced immunomodulation [35]. 
Wermerskirchen et al. reports that ACTH modulates in 
vitro IL-2 secretion from activated splenic lymphocytes 
(Cytotoxic T Lymphocytes Leukemia cells CTLL-2) 
and indicates two-directional action (suppression and 
activation) according to the concentration changes 
[36]. Serum Il-2 receptor level was also reported to rise 
during pregnancy [10]. It was also noticed that ACTH 
modulates macrophages function [8], and macrophages 
changes in decidua were identified during spontane-
ous labor (Sindram 2004). HPA axis is also involved in 
the pathogenesis of treatment-resistant depression, in 
which this patient presents disturbance of the activa-
tion of lymphocytes function [25]. Immunomodulating 
activity is also characteristic for oxitocinase [27]. Sta-
tistically significantly higher oxytocinase serum level 
was found a few days before induced labor in compari-
son to spontaneous labor in previous studies [21,37]. 
Spontaneous labor requires the termination of mater-
nal immunological tolerance to fetal antigens, and the 
activation of cytotoxic immune response [11,37]. The 
ACTH growing level seems to result from these changes 
in maternal immune response. 
Preeclampsia seems to be secondary to anomaly of 
the the uterine spiral arteries invasions by cytotropho-
blast cells and finnaly results in hypertension [1,28]. 
One of biological effects of oxytocinase activity is the 
regulation of placental blood flow, what was confirmed 
by simultaneous assessment of CAP serum level and 
Doppler ultrasound examination [16,22]. In our previ-
ous research CAP1 and CAP2 serum decreased levels 
in patients with preeclampsia were confirmed [6,21]. 
Among other vasomotor factors like NO, ET-1 (endo-
thelin-1), CAP1 seems to appear as an important factor 
regulating the placental blood flow. Elevated ACTH 
level was identified in the umbilical artery in pregnan-
cies complicated by preeclampsia or IUGR [5,28].
In conclusion, the assessment of ACTH and CAP 
might be useful for the evaluation of pregnancy devel-
opment. 
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